Blog


Although solid dosage forms like tablets and capsules continue to dominate the global pharmaceutical market, many people find them challenging to take. There is evidence to suggest that oral liquid dosage forms may offer untapped opportunities, with the potential to: improve patient experiences and compliance reduce healthcare costs create new revenue streams. In a study[…]

Read More

As the global population ages, we’ll see an increase in the demand for SSDs or topical drugs. And as drug companies innovate, the semi-solid dose will fill needs that other forms cannot.

  For decades, the most popular form of drug dosage has consistently remained oral solids —the tablet, the pill, the capsule. This trend is likely to continue, but the oral solid’s unassuming younger sibling – the semi-solid dose (SSD) – is making some noise. The semi-solids market is growing, and will continue to grow, over[…]

Read More

Drug approvals are often complex and time-consuming, even for generic versions of approved medications. Some of this complexity is unavoidable for good reasons, especially when it comes to patient safety. Much of the process is specifically designed to minimize the chance that new drugs – or new versions of existing ones – will cause harm.

Drug approvals are often complex and time-consuming, even for generic versions of approved medications. Some of this complexity is unavoidable for good reasons, especially when it comes to patient safety. Much of the process is specifically designed to minimize the chance that new drugs – or new versions of existing ones – will cause harm.[…]

Read More

Oral solid dosage forms (OSDFs), notably capsules and tablets, continue to be the most popular drug form used worldwide.

Oral solid dosage forms (OSDFs), notably capsules and tablets, continue to be the most popular drug form used worldwide. Here are some common questions and insights from Deepak Thassu, VP of LGM Pharma’s R&D and Regulatory Division, about OSDF use and manufacturing. 1. Why do OSDFs dominate the global pharmaceutical market? Solid dosage forms may[…]

Read More

LGM Helps Pharma Manage Supply Chain Risks with Added Services Through Nexgen Acquisition

COVID-19 has put supply chain risk management practices under the microscope. Coming on the heels of many other, more localized supply issues in the last decade, it has brought about a near-global assessment that supply chains need to be more tightly controlled and redundant – and less dependent on external, at-risk suppliers. In a sense,[…]

Read More

LGM Pharma’s Expanded Contract Development and Manufacturing Organization (CDMO) Capabilities Will Enable Customers to Accelerate and Optimize the New Product Pathway from Early Development Through Commercialization Boca Raton, Florida, July 27, 2020 – LGM Pharma today announced that it has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. The[…]

Read More

What are the risks the U.S. faces with our current supply chains spread across the globe?

When SARS-CoV-2 arrived on American shores this Spring, concerns about overextended drug supply chains already were circulating. The issues at hand weren’t new, by any stretch. Environmental, quality and political actions all had impacted drug imports in the last half-dozen years, causing drug shortages and C-suite anxiety. The global pandemic – and the resultant (albeit[…]

Read More

Risk Management Practices

It may seem odd to be discussing sourcing challenges considering the overwhelming evidence we now have of what can happen to global (and even local) supply chains when disaster strikes, but while the coronavirus pandemic certainly has put the spotlight on the risks of global supply chains, it by no means created those risks. Indeed,[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service